Fig. 2: CD84-targeting CART cells are successfully generated and expanded. | Leukemia

Fig. 2: CD84-targeting CART cells are successfully generated and expanded.

From: A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias

Fig. 2

A Scheme of second-generation CAR vector with EF1-α promoter, anti-human CD84 single-chain variable fragment (scFv), CD8α as hinge (H), and transmembrane (TM) domain, 4-1BB as intracellular costimulatory domain, and CD3ζ as signaling domain. B Population doubling of CART84 cells in comparison to UT cells at day 6 of expansion (Min to Max) n = 5–13. C Percentage of CAR-positive cells in CART84 cells at day 6 of expansion (Mean ± SD) n = 9–17. Cytotoxicity of CART84 towards different cell lines: CD84high MOLM-13-GFP+ (AML) (D); CD84low U937-GFP+ (AML) (E); CD84high MOLT-4-GFP+ (T-ALL) (F); CD84high Ramos-GFP+ (Burkitt lymphoma) (G). The percentage of surviving target cells relative to untreated cells (target cells alone) is shown at different effector-to-target (E:T) ratios at 24 h. Mean of at least 5 independent experiments ± SEM. UT untransduced T cells. Statistical significance was determined with a two-way ANOVA test (multiple comparisons to UT): ***p < 0.001, **p < 0.01, *p < 0.05.

Back to article page